Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chimeric antigen receptor therapies: Development, design, and implementation.

Madeline J Lee1, Frank Cichocki1, Jeffrey S Miller1

  • 1Department of Medicine, University of Minnesota, Minneapolis, Minn.

The Journal of Allergy and Clinical Immunology
|April 12, 2025
PubMed
Summary

Chimeric antigen receptor (CAR) T and NK cell therapies show promise for cancer treatment but face limitations, especially in solid tumors. This review explores CAR therapy development, design, and future advancements for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.

Neuro-oncology·2026
Same author

Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIV.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cells.

Cell reports. Medicine·2026
Same author

Can natural killer cells cure leukemia?

Leukemia·2026
Same author

HIV tri-specific killer engagers directly enhance NK cell function and safely expand NK cells in vivo.

Cell reports. Medicine·2026
Same author

Reprogramming endogenous NK circuits by highly efficient nonviral genome editing.

The Journal of experimental medicine·2026

Area of Science:

  • Immunotherapy
  • Cellular Therapy
  • Oncology

Background:

  • Chimeric antigen receptor (CAR) T and natural killer (NK) cell therapies offer targeted cancer treatment by engineering immune cells to recognize specific antigens.
  • These therapies have demonstrated significant success in hematologic malignancies but show limited efficacy in solid tumors and for non-responsive patient populations.

Purpose of the Study:

  • To provide a comprehensive overview of CAR T and NK cell therapy development, from initial research to clinical application.
  • To discuss the components of CAR constructs, optimization strategies, and cell sources for these advanced therapies.
  • To examine the current limitations of CAR T and CAR NK cells and explore recent breakthroughs and future directions.

Main Methods:

  • Literature review of CAR T and NK cell therapy research.
Keywords:
CAR NK cellsCAR T cellscancerimmunotherapy

Related Experiment Videos

  • Analysis of CAR construct design and engineering principles.
  • Examination of clinical outcomes and challenges in CAR therapy.

    • Main Results:

    • CAR T and NK cells are effective against certain blood cancers but face challenges in solid tumor treatment.
    • CAR construct design and cell source selection are critical for optimizing therapeutic efficacy.
    • Ongoing research is addressing limitations and exploring new avenues for CAR therapy.

    Conclusions:

    • CAR T and NK cell therapies hold significant potential for treating various diseases, including cancers.
    • Further research and development are crucial to overcome existing limitations and expand the application of CAR therapies.
    • Recent breakthroughs suggest a promising future for CAR therapies in improving patient outcomes across a broader range of diseases.